Bruker Corporation — FY2020 Form 10-K
Business context and reporting period. Bruker develops and sells scientific instruments, analytical and diagnostic solutions, and superconducting materials. It reports three segments: BSI Life Science, BSI NANO, and BEST. This summary covers the fiscal year ended December 31, 2020, compared primarily with FY2019. The company attributed a material portion of the year’s performance to the COVID-19 pandemic and related economic slowdown.
Key financial results
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Revenue | $1,987.5 million | $2,072.6 million | Down 4.1%; organic revenue down 6.0% |
| Gross profit / margin | $939.8 million / 47.3% | $995.3 million / 48.0% | Margin down 0.7 percentage points |
| Operating income / margin | $248.3 million / 12.5% | $300.9 million / 14.5% | Margin down 2.0 percentage points |
| Net income attributable to Bruker | $157.8 million | $197.2 million | Down 20.0% |
| Diluted EPS | $1.02 | $1.26 | Down 19.0% |
| Cash from operations | $332.2 million | $213.4 million | Up $118.8 million |
| Free cash flow (non-GAAP) | $235.0 million | $140.4 million | Up 67% |
| Cash, cash equivalents and short-term investments | $731.8 million | $684.9 million | Up $46.9 million |
| Total debt (carrying amount) | $844.5 million | $813.3 million | Up $31.2 million |
Free cash flow is a company-defined non-GAAP measure, calculated as operating cash flow less purchases of property, plant and equipment. FY2020 capital expenditures were $97.2 million. The company reported $599.9 million available under its $600 million revolving credit facility at year-end, and said it was in compliance with debt covenants and expected existing cash and credit facilities to support operating and investing needs for at least 12 months. Approximately $514.9 million, or 70.4%, of cash, cash equivalents and short-term investments was held by foreign subsidiaries.
Segment performance and material changes
- BSI Life Science: Revenue was $1,253.9 million, up 0.7%; operating income was $273.8 million versus $290.3 million. Demand for microbiology and infectious-disease diagnostics and certain mass spectrometry systems offset declines in BioSpin systems and molecular spectroscopy.
- BSI NANO: Revenue was $556.1 million, down 12.1%; operating income was $23.6 million versus $40.4 million. Bruker cited weaker academic and industrial research demand and pandemic-related disruption.
- BEST: Revenue was $189.5 million, down 9.7%; operating income was $6.2 million versus $16.4 million, reflecting lower superconductor demand, unfavorable mix and restructuring charges.
Product revenue fell 6.1% to $1,638.1 million, while service revenue increased 6.5% to $343.4 million. Reported revenue included a favorable $29.4 million foreign-currency impact and $10.5 million from recent acquisitions; excluding currency and acquisitions, organic revenue declined $125.0 million. The effective tax rate decreased to 28.5% from 29.4%. Management cited jurisdictional income mix and the GILTI high-tax election, partly offset by a valuation-allowance change.
Operating cash flow benefited from increased customer advances and collections, despite lower net income; inventory increased $91.6 million. The year-end backlog was approximately $2,006.7 million, up from $1,855.3 million, with about 67.3% expected to be filled in 2021. Backlog is not necessarily a reliable indicator of long-term revenue.
Outlook, risks and unusual items
- Management said the pandemic’s duration, severity, possible resurgences or new strains, and effects on customers, suppliers and operations made the 2021 impact difficult to predict. No specific revenue or earnings guidance was provided in the supplied filing text.
- Management expected 2021 capital expenditures of approximately $100 million. It reported higher inventory to address supply-chain risks and said it did not anticipate being supply- or capacity-limited in the first quarter of 2021.
- COVID-19 disrupted customer access, travel, installations, shipments and manufacturing productivity. Temporary cost measures included reduced work hours, salary reductions, hiring and discretionary-spending controls, and temporary facility closures; many measures had subsequently been relaxed.
- Other key risks include reliance on international markets and government or academic research funding, competition and rapid technological change, dependence on sole- or limited-source suppliers, foreign-exchange and commodity-price exposure, debt and covenant requirements, and medical-device and export regulation.
- FY2020 other charges, net were $24.9 million, including $12.0 million of restructuring costs, $5.9 million of professional fees, $2.5 million for the global IT transformation, $2.4 million of acquisition-related charges and $2.1 million of long-lived asset impairments. The company reported no goodwill impairment.
- The company acquired Canopy Biosciences and other businesses and bought the remaining 20% interest in Hain LifeScience. It repurchased 2.7 million shares for $123.2 million and paid $24.6 million in dividends. The annual dividend target was $0.16 per share, subject to board approval.
- Bruker was defending patent suits involving Luxendo and the timsTOF product line; management did not expect material losses beyond amounts accrued in the timsTOF matter. The filing states that pending proceedings were not expected to have a material impact. A related-party purchase of two Billerica properties from trusts controlled by the CEO and a family member totaled $12.3 million and was approved by the Audit Committee.
- Previously disclosed material weaknesses in income-tax accounting and revenue recognition controls were reported as remediated in 2020. Management and the auditor concluded internal control over financial reporting was effective at year-end; the assessment excluded two small 2020 acquisitions.
Important facts for investors to verify
- Whether the recovery in orders and the larger backlog converted into revenue and cash in 2021, including customer installation and acceptance timing.
- Whether gross and operating margins recover from FY2020 levels, and how restructuring and temporary cost actions affect ongoing expenses.
- Cash availability and repatriation: most cash and short-term investments were held outside the United States, while debt service and other funding needs include U.S. requirements.
- Debt maturities, interest costs, covenant headroom and the transition away from LIBOR; reported debt carrying value and contractual-obligation figures differ in the filing.
- Exposure to foreign exchange, supply constraints and raw-material prices, and the progress of regulatory recertification for in-vitro diagnostic products.
- Developments in the patent litigation, tax positions and unrecognized withholding taxes, acquisition integration, and remaining share-repurchase authorization.